In focus
Latest feed
Regeneron and Tessera Forge Potent Alliance for Next-Generation Gene Editing Therapies
A Bold Bet on the Future: Regeneron's $150M Investment in Gene Writing
A New Dawn for Knee Surgery? Unpacking Regeneron's Game-Changing Clot Prevention
Regeneron's Remarkable Q3: A Dupixent-Driven Triumph That Reaffirms Biotech's Pulse
